Impact of active pulmonary tuberculosis on overall survival among adult patients with B-cell non-Hodgkin lymphoma
DOI:
https://doi.org/10.69898/jhtm.35.2025.276387Keywords:
pulmonary tuberculosis, overall survival, B-cell non-Hodgkin lymphoma, risk factorAbstract
Introduction: Patients with B-cell non-Hodgkin lymphoma (B-cell NHL) have an increased risk of developing active tuberculosis (TB) during treatment. Active pulmonary TB among patients with B-cell NHL often leads to poor outcomes. Objective: The primary objective was to compare the 3-year overall survival (OS) of patients with B-cell NHL and active pulmonary TB to those without active pulmonary TB. The secondary objective was to investigate the association of active pulmonary TB with mortality risk among patients with B-cell NHL. Materials and Methods: A retrospective cohort was conducted on patients with newly diagnosed B-cell NHL at Chiangrai Prachanukroh Hospital from January 2016 to December 2023. OS rates were estimated using the Kaplan-Meier method and compared between groups using the two-sided log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk factors associated with mortality. Results: A total of 415 patients were enrolled, with a mean age of 58.96 years. Among them, 19 (4.58%) developed active pulmonary TB after their B-cell NHL diagnosis and during treatment. Patients with active pulmonary TB had significantly worse 3-year OS compared to those without active pulmonary TB (22.39% vs. 55.11%, p < 0.001). The median follow-up time was 89 weeks. Active pulmonary TB was associated with an increased risk of mortality (HR, 1.80, 95% CI, 1.01-3.21). Conclusion: Active pulmonary TB among adult patients with B-cell NHL is associated with worse survival outcomes and represents an independent risk factor for mortality.
Downloads
References
Raviglione M, Sulis G. Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination. Infect Dis Rep. 2016;8:6570.
Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet. 2016;387:1211-26.
World Health Organization. 2015 Global Tuberculosis Report. Geneva, Switzerland: WHO, 2015.
World Health Organization. 2023 Global Tuberculosis Report. Geneva, Switzerland: WHO, 2023.
World Health Organization. 2022 Global Tuberculosis Report. Geneva, Switzerland: WHO, 2022.
Global tuberculosis report 2024. Geneva: World Health Organization; 2024.
Division of Tuberculosis. National Tuberculosis Control Programme Guideline, Thailand 2021. Bangkok: Division of Tuberculosis; 2021.
Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010;50 Suppl 3:S201-7.
Dobler CC, McDonald SP, Marks GB. Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One. 2011;6:e29563.
Dobler CC, Flack JR, Marks GB. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open. 2012;2:e000666.
Dobler CC. Biologic Agents and Tuberculosis. Microbiol Spectr. 2016;4.
Dobler CC. Biological agents and tuberculosis: risk estimates and screening strategies. Int J Rheum Dis. 2015;18:264-7.
Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, et al. Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2017;64:635-44.
Wu CY, Hu HY, Pu CY, Huang N, Shen HC, Li CP, et al. Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study. Int J Tuberc Lung Dis. 2011;15:125-30.
Mancuso S, Mattana M, Carlisi M, Santoro M, Siragusa S. Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy. Int J Mol Sci. 2022;23:3368.
Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of Malnutrition. Trends Immunol. 2016;37:386-98.
Dobler CC, Cheung K, Nguyen J, Martin A. Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. Eur Respir J. 2017;50:1700157.
Roy P, BalaK, Biswas J, Ahmed J, Bir R, Yadav V, et al. Active Tuberculosis Risk Associated with Malignancies: A4-Year Retrospective Study in aTertiary Care Hospital. South Asian J Cancer 2024;00:00.
Hung CL, Su CC, Ou CY. Impact of active pulmonary tuberculosis on the prognosis of patients with upper aerodigestive cancers: An 8-year observational study in a nationwide cohort. J Infect Public Health. 2022;15:1540-5.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-90.
Cheon J, Kim C, Park EJ, Ock M, Lee H, Ahn JJ, et al. Active tuberculosis risk associated with malignancies: an 18-year retrospective cohort study in Korea. J Thorac Dis. 2020;12:4950-9.
Chen CY, Sheng WH, Cheng A, Tsay W, Huang SY, Tang JL, et al. Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infect Dis. 2011;11:324.
Nanthanangkul S, Promthet S, Suwanrungruang K, Santong C, Vatanasapt P. Incidence of and Risk Factors for Tuberculosis among Cancer Patients in Endemic Area: A Regional Cohort Study. Asian Pac J Cancer Prev. 2020;21:2715-21.
Silva FA, Matos JO, de Q Mello FC, Nucci M. Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances. Haematologica. 2005;90:1110-5.
Cliffton EE, Irani BB. Pulmonary tuberculosis and cancer. N Y State J Med. 1970;70:274-8.
Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer. 1974;33:850-8.
Stefan DC, Kruis AL, Schaaf HS, Wessels G. Tuberculosis in oncology patients. Ann Trop Paediatr. 2008;28:111-6.
Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592-5.
Pagano L, Caira M, Rossi G, Tumbarello M, Fanci R, Garzia MG, et al. A prospective survey of febrile events in hematological malignancies. Ann Hematol. 2012;91:767-74.
Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013;368:745-55.
Sánchez-Ramón S, Bermúdez A, González-Granado LI, et al. Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management. Front Immunol. 2019;10:586.
Brett K, Dulong C, Severn M. Tuberculosis in People with Compromised Immunity: A Review of Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020.
Cliff JM, Kaufmann SH, McShane H, van Helden P, O'Garra A. The human immune response to tuberculosis and its treatment: a view from the blood. Immunol Rev. 2015;264:88-102.
Al-Anazi KA, Al-Jasser AM, Alsaleh K. Infections Caused by Mycobacterium tuberculosis in Recipients of Hematopoietic Stem Cell Transplantation. Front Oncol. 2014;4:231.
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington SF, Zaucha JM, et al. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. Blood Adv. 2022;6:5995-6004.
Dzis I, Tomashevska O, Dzis Y, Korytko Z. Prediction of survival in non-Hodgkin lymphoma based on markers of systemic inflammation, anemia, hypercoagulability, dyslipidemia, and Eastern Cooperative Oncology Group performance status. Acta Haematol Pol 2020;51:34-41.
Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center. Ann Hematol. 2012;91:1603-11.
Wang Y, Shi Q, Shi ZY, Tian S, Zhang MC, Shen R, et al. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma. Blood Adv. 2024 Apr 9;8:1587-99.
Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15:61.
Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med (Berl). 2016;94:509-22.
Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control. 2008;19:841-58.
Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135:2041-8.
D'Angelo CR, Hanel W, Chen Y, Yu M, Yang D, Guo L, et al. Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. Hematol Oncol. 2021;39:473-82.
Wästerlid T, Mohammadi M, Smedby KE, Glimelius I, Jerkeman M, Bottai M, et al. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study. J Intern Med. 2019;285:455-68.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-61.
Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22-32.
Shieh SH, Probst JC, Sung FC, Tsai WC, Li YS, Chen CY. Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes. BMC Cancer. 2012;12:174.
Anibarro L, Pena A. Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis. 2014;6:e2014026.
Ellin F, Maurer MJ, Srour L, Farooq U, Jerkeman M, Connors JM, et al. Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. Br J Haematol. 2019;186:e24-e27.
Yang Y, Wang L, Ma Y, Han T, Huang M. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma. Am J Med Sci. 2017;353:459-65.
Betjes MG, Meijers RW, Litjens NH. Loss of renal function causes premature aging of the immune system. Blood Purif. 2013;36:173-8.
Ubukata M, Hara M, Nishizawa Y, Fujii T, Nitta K, Ohta A. Prevalence and mortality of chronic kidney disease in lymphoma patients: A large retrospective cohort study. Medicine (Baltimore). 2018;97:e9615.
Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, et al. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS One. 2017;12:e0186549.
Baptista MJ, Garcia O, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, et al. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. AIDS. 2015;29:811-8.
Taplitz R, Galasso JA, Medley K. Implementing a Screening and Treatment Protocol for Latent Tuberculosis in Patients with Hematologic Malignancies in a Southern California Medical Center. Biology of Blood and Marrow Transplantation. 2015; 21: S240eS265.
Anibarro L, Pena A. Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis. 2014;6:e2014026.
Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med. 2019;40:839-48.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
